Prevalence and Risk Factors for Colonization with Carbapenem-Resistant Microorganisms in Patients Admitted to a Multidisciplinary Hospital

Relevance. In the last decade, there has been an increase in the isolation of antibiotic-resistant microorganisms in community settings. Colonization and asymptomatic carriage of extended-spectrum beta-lactamase and carbapenemase producers can be a precursor to the development of an infectious process and a significant factor in the pathogenesis of healthcare-associated infections. Understanding the risk factors for community-acquired colonization with antibiotic-resistant microorganisms is necessary for targeted screening and timely implementation of measures to prevent the spread of resistance in hospitals.
The aim. To determine significant risk factors for colonization with antibiotic-resistant gram-negative microorganisms and carriage of carbapenem resistance genes in patients admitted to a multidisciplinary hospital.
Materials & Methods. A prospective single-center crosssectional study was conducted at the Moscow Multidisciplinary Clinical Center «Kommunarka» from 15.09.2022 to 15.08.2023. The study included 733 patients aged 18 to 94 years. Biological samples were taken from the rectum, upper and lower respiratory tract. The obtained samples were examined by real-time polymerase chain reaction (PCR) with hybridization-fluorescent detection of amplification products to identify carbapenemase genes and by culture method to determine colonization with carbapenemresistant bacteria. Identification of isolated microorganisms was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and antibiotic susceptibility was determined by the Kirby-Bauer disk diffusion method on Mueller-Hinton agar. The results of susceptibility testing were interpreted based on EUCAST v12.0, v13.0, and v13.1 criteria.
Results. Carriage of carbapenemase genes was detected in 12.6% of patients admitted to the hospital, while colonization with carbapenem-resistant bacteria was found in 2.7%. In the majority of patients (66.7%), the rectum was the only site of gene carriage. However, only 18.1% of these patients showed rectal colonization with carbapenem-resistant bacteria. This discrepancy is likely due to the higher sensitivity of molecular genetic methods compared to culture-based techniques. From a clinical perspective, the detection of nucleic acids by PCR can serve as an equivalent to pathogen detection in biological material. Multivariate analysis identified 5 independent predictors of colonization: cytostatic therapy, transfer from another hospital, need for vasopressor support, antibiotic use in the previous 3 months, and male gender.
Conclusion. The identified risk factors allow for the identification of a highrisk patient cohort for targeted screening, enabling timely administration of appropriate antibiotic therapy and implementation of measures to prevent the spread of carbapenem resistance in the hospital.

1. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. [Internet] Available at: https://www.who.int/news/item/27–02–2017–who–publishes–list–of–bacteria–for–which–new–antibiotics–are–urgently–needed. Accessed: 5 Aug 2024.

2. Kozlov RS, Kuzmenkov AY, Vinogradova AG. Antibiotic resistance as a medical problem. Vestnik Rossijskoj akademii nauk. 2024;94(1):11–18 (In Russ). doi: 10.31857/S0869587324010033

3. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths Attributable to Carbapenem–Resistant Enterobacteriaceae Infections. Emerging Infectious Diseases. 2014;20(7):1170–1175. doi:10.3201/eid2007.121004.

4. Otter JA, Burgess P, Davies F, et al. Counting the cost of an outbreak of carbapenemase–producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188–196. doi:10.1016/j.cmi.2016.10.005

5. Cerceo E, Deitelzweig SB, Sherman BM, et al. Multidrug–Resistant Gram–Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist. 2016;22(5):412–431. doi:10.1089/mdr.2015.0220

6. Devi LS, Broor S, Rautela RS, et al. Increasing Prevalence of Escherichia coli and Klebsiella pneumoniae Producing CTX–M–Type Extended–Spectrum Beta–Lactamase, Carbapenemase, and NDM–1 in Patients from a Rural Community with Community Acquired Infections: A 3–Year Study. Int J Appl Basic Med Res. 2020;10(3):156–163. doi:10.4103/ijabmr.IJABMR_360_19

7. Dickstein Y, Edelman R, Dror T, et al. Carbapenem–resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non–carriers. J Hosp Infect. 2016;94(1):54–59. doi:10.1016/j.jhin.2016.05.018

8. McConville TH, Sullivan SB, Gomez–Simmonds A, et al. Carbapenem–resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90–day mortality in critically ill patients, an observational study. PLoS One. 2017;12(10):e0186195. doi:10.1371/journal.pone.0186195

9. Emmanuel Martinez A, Widmer A, Frei R, et al. ESBL–colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcome. Infect Control Hosp Epidemiol. 2019;40(4):408–413. doi:10.1017/ice.2019.5

10. Golzarri MF, Silva–Sánchez J, Cornejo–Juárez P, et al. Colonization by fecal extended–spectrum β-lactamase–producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control. 2019;47(8):916–921. doi:10.1016/j.ajic.2019.01.020

11. Massart N, Camus C, Benezit F, et al. Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta–lactamase–producing Gram–negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate. Eur J Clin Microbiol Infect Dis. 2020;39(5):889–895. doi:10.1007/s10096–019–03800–y

12. EUCAST. Clinical breakpoints – breakpoints and guidance. Archive of EUCAST tables and documents. [Internet]. Available at: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents. Accessed: 5 Aug 2024.

13. About Carbapenem–resistant Enterobacterales. [Internet]. Available at: https://www.cdc.gov/cre/about/index.html. Accessed: 5 Aug 2024.

14. Edelstein MV. Detection of Extended Spectrum β–lactamases by Phenotypic Methods in Gram–negative Bacteria. Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia. 2001;3(2): 183–189. (In Russ).

15. Hu Y, Qing Y, Chen J, et al. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem–Resistant Pseudomonas aeruginosa. Microbiol Spectr. 2021;9(3):e0134421. doi:10.1128/Spectrum.01344–21

16. Ed.: Yakovlev S.V., Briko N.I., Sidorenko S.V., et al. AMS program (Strategy for the Control of Antimicrobial Therapy) in the provision of inpatient medical care. Russian clinical guidelines. Moscow: Pero; 2018 (In Russ).

17. Yan L, Sun J, Xu X, Huang S. Epidemiology and risk factors of rectal colonization of carbapenemase–producing Enterobacteriaceae among high risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control. 2020;9(1):155. doi:10.1186/s13756–020–00816–4

18. Kim HJ, Hyun J, Jeong HS, et al. Epidemiology and Risk Factors of Carbapenemase–Producing Enterobacteriaceae Acquisition and Colonization at a Korean Hospital over 1 Year. Antibiotics (Basel). 2023;12(4):759. doi:10.3390/antibiotics12040759

19. Rodríguez–Villodres Á, Martín–Gandul C, Peñalva G, et al. Prevalence and Risk Factors for Multidrug–Resistant Organisms Colonization in Long–Term Care Facilities Around the World: A Review. Antibiotics (Basel). 2021;10(6):680. doi:10.3390/antibiotics10060680

20. Kajova M, Khawaja T, Kantele A. European hospitals as source of multidrug–resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad. J Travel Med. 2022;29(4):taac022. doi:10.1093/jtm/taac022

21. Heinemann M, Kleinjohann L, Rolling T, et al. Impact of antibiotic intake on the incidence of extended–spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa: results from a community based longitudinal study. Clin Microbiol Infect. 2023;29(3):340–345. doi:10.1016/j.cmi.2022.09.008

22. Bar Ilan M, Kjerulf A. Who should be screened for carbapenemase–producing Enterobacterales and when? A systematic review. J Hosp Infect. 2023;142:74–87. doi:10.1016/j.jhin.2023.09.018

23. Kozlov RS, Vinogradov AG, Kuzmenkov AYu, et al., editors. Monitoring antibiotikorezistentnosti s ispol’zovaniem platformy AMRcloud. Prakticheskoe rukovodstvo. Smolensk: SGMU;2021 (In Russ).

24. Kelly AM, Mathema B, Larson EL. Carbapenem–resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017;50(2):127–134. doi:10.1016/j. ijantimicag.2017.03.012

25. Garrido A, Seral C, Gude MJ, et al. Characterization of plasmid–mediated β–lactamases in fecal colonizing patients in the hospital and community setting in Spain. Microb Drug Resist. 2014;20(4):301–304. doi:10.1089/mdr.2013.0109

26. Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram–positive cocci and gram–negative multidrug–resistant bacteria in spontaneous bacterial peritonitis. Liver Int. 2013;33(7):975–981. doi:10.1111/liv.12152

27. Lohiya A, Kant S, Kapil A, et al. Pattern of Antibiotic Resistance Among Community Derived Isolates of Enterobacteriaceae Using Urine Sample: A Study From Northern India. J Clin Diagn Res. 2015;9(7):LC15–LC19. doi:10.7860/JCDR/2015/14230.6254

28. Henderson J, Ciesielczuk H, Nelson SM, et al. Community prevalence of carbapenemase–producing organisms in East London. J Hosp Infect. 2019;103(2):142–146. doi:10.1016/j.jhin.2019.04.014

29. van den Bunt G, van Pelt W, Hidalgo L, et al. Prevalence, risk factors and genetic characterisation of extended–spectrum beta–lactamase and carbapenemase–producing Enterobacteriaceae (ESBL–E and CPE): a community–based cross–sectional study, the Netherlands, 2014 to 2016. Euro Surveill. 2019;24(41):1800594. doi:10.2807/1560–7917. ES.2019.24.41.1800594

30. Turnidge JD, Gottlieb T, Mitchell DH, et al. Australian Group on Antimicrobial Resistance Community–onset Gram–negative Surveillance Program annual report, 2010. Commun Dis Intell Q Rep. 2013;37(3):E219–E223.

31. Sheng WH, Badal RE, Hsueh PR; et al. Distribution of extended–spectrum β–lactamases, AmpC β–lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia–Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–2988. doi:10.1128/AAC.00971–12

32. Tang HJ, Hsieh CF, Chang PC, et al. Clinical Significance of Community– and Healthcare–Acquired Carbapenem–Resistant Enterobacteriaceae Isolates. PLoS One. 2016;11(3):e0151897. doi:10.1371/journal.pone.0151897

33. Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem–resistant Enterobacteriaceae in a community hospital: Development of a bedside clinical score for risk assessment. Am J Infect Control. 2016;44(2):134–137. doi:10.1016/j.ajic.2015.09.006

34. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of Carbapenem–Resistant Enterobacteriaceae in 7 US Communities, 2012–2013. JAMA. 2015;314(14):1479–1487. doi:10.1001/jama.2015.12480

35. Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem–resistant enterobacteriaceae in community hospitals: a mixed–methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35(8):978–983. doi:10.1086/677157

36. Brennan BM, Coyle JR, Marchaim D, et al. Statewide surveillance of carbapenem–resistant enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35(4):342– 349. doi:10.1086/675611

37. Li K, Jiang S, Fu H, et al. Risk Factors and Prognosis of Carbapenem–Resistant Organism Colonization and Infection in Acute Cholangitis. Infect Drug Resist. 2022;15:7777–7787. doi:10.2147/IDR.S398581

38. Tian F, Li Y, Wang Y, et al. Risk factors and molecular epidemiology of fecal carriage of carbapenem resistant Enterobacteriaceae in patients with liver disease. Ann Clin Microbiol Antimicrob. 2023;22(1):10. doi:10.1186/s12941–023–00560–8

39. Satlin MJ, Chen L, Gomez–Simmonds A, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime–Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem–Resistant Enterobacterales. Clin Infect Dis. 2022;75(12):2066–2075. doi:10.1093/cid/ciac354

40. Recio R, Villa J, Viedma E, et al. Bacteraemia due to extensively drug–resistant Pseudomonas aeruginosa sequence type 235 high–risk clone: Facing the perfect storm. Int J Antimicrob Agents. 2018;52(2):172–179. doi:10.1016/j.ijantimicag.2018.03.018

41. Baier C, Beck M, Panagiota V, et al. Infection control management and surveillance of carbapenem–resistant Gram–negative bacteria in hematopoietic stem cell recipients. Antimicrob Resist Infect Control. 2019;8:160. doi:10.1186/s13756–019–0606–3

42. Cattaneo C, Di Blasi R, Skert C, et al. Bloodstream infections in haematological cancer patients colonized by multidrug–resistant bacteria. Ann Hematol. 2018;97(9):1717–1726. doi:10.1007/s00277–018–3341–6

43. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem–resistant Acinetobacter baumannii: A challenge in the intensive care unit. Front Microbiol. 2022;13:1045206. doi:10.3389/fmicb.2022.1045206

44. Hu H, Wang Y, Sun J, et al. Risk factors and molecular epidemiology of intestinal colonization by carbapenem–resistant Gram–negative bacteria in patients with hematological diseases: a multicenter case‒control study. Microbiol Spectr. 2024;12(7):e0429923. doi:10.1128/spectrum.04299–23

45. Kuzmenkov AYu., Vinogradova AG., Trushin IV., et al. AMRmap – antibiotic resistance surveillance system in Russia. Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia. 2021; 23(2):198–204 (In Russ). doi:10.36488/cmac.2021.2.198–204

46. Lautenbach E, Mosepele M, Smith RM, et al. Risk Factors for Community Colonization With Extended–Spectrum Cephalosporin–Resistant Enterobacterales (ESCrE) in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study. Clin Infect Dis. 2023;77(Suppl 1):S89–S96. doi:10.1093/cid/ciad259

47. Caudell MA, Castillo C, Santos LF, et al. Risk factors for colonization with extended–spectrum cephalosporin–resistant and carbapenem–resistant Enterobacterales among hospitalized patients in Guatemala: An Antibiotic Resistance in Communities and Hospitals (ARCH) study. IJID Reg. 2024;11:100361. doi:10.1016/j.ijregi.2024.100361

48. Moghnieh R, Abdallah D, Jadayel M, et al. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci Rep. 2021;11(1):14757. doi:10.1038/s41598–021–94295–1

49. Park SH, Yi Y, Suh W, Ji SK, Han E, Shin S. The impact of enhanced screening for carbapenemase–producing Enterobacterales in an acute care hospital in South Korea. Antimicrob Resist Infect Control. 2023;12(1):62. doi:10.1186/s13756–023–01270–8

50. Klyasova GA, Korobova AG, Frolova IN, et al. Detection of extended–spectrum β-lactamase producing Enterobacteriaceae (ESBL–E) among patients with acute myeloid leukemia and lymphoma upon admission to hospital. Russian journal of hematology and transfusiology. 2016;61(1):25–32 (In Russ.). https://doi.org/10.18821/0234–5730–2016–61–1–25–32

51. Segagni Lusignani L, Presterl E, Zatorska B, et al. Infection control and risk factors for acquisition of carbapenemase producing enterobacteriaceae. A 5 year (2011–2016) case–control study. Antimicrob Resist Infect Control. 2020;9(1):18. doi:10.1186/s13756–019–0668–2

52. Salomão MC, Freire MP, Boszczowski I, et al. Increased Risk for Carbapenem–Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department. Emerg Infect Dis. 2020;26(6):1156–1163. doi:10.3201/eid2606.190965

53. Callejón Fernández M, Madueño Alonso A, Abreu Rodríguez R, et al. Risk factors for colonization by carbapenemase–producing bacteria in Spanish long–term care facilities: a multicentre point–prevalence study. Antimicrob Resist Infect Control. 2022;11(1):163. doi:10.1186/s13756–022–01200–0

54. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–599.

55. van Duin D, Paterson DL. Multidrug–Resistant Bacteria in the Community: An Update. Infect Dis Clin North Am. 2020;34(4):709–722. doi:10.1016/j.idc.2020.08.002

56. Shrestha R, Luterbach CL, Dai W, et al. Characteristics of community–acquired carbapenem–resistant Enterobacterales. J Antimicrob Chemother. 2022;77(10):2763–2771. doi:10.1093/jac/dkac239

57. Salomão MC, Guimarães T, Duailibi DF, et al. Carbapenem–resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect. 2017;97(3):241–246. doi:10.1016/j.jhin.2017.08.012

58. Barbadoro P, Bencardino D, Carloni E, et al. Carriage of Carbapenem–Resistant Enterobacterales in Adult Patients Admitted to a University Hospital in Italy. Antibiotics (Basel). 2021;10(1):61. doi:10.3390/antibiotics10010061

59. van Loon K, Voor In ‘t Holt AF, Vos MC. A Systematic Review and Meta–analyses of the Clinical Epidemiology of Carbapenem–Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62(1):e01730–17. doi:10.1128/AAC.01730–17